Literature DB >> 6423228

Clomiphene protects against osteoporosis in the mature ovariectomized rat.

P T Beall, L K Misra, R L Young, H J Spjut, H J Evans, A LeBlanc.   

Abstract

Clomiphene citrate, a mixed estrogen agonist-antagonist, protects mature ovariectomized breeder rats from changes in total body calcium and from deterioration of femur structure. Over 6 months, mature ovariectomized rats took up calcium at the rate of 0.7 +/- 0.5 mg/day, while normal controls gained 2.5 +/- 0.7 mg/day (mean +/- SEM) as measured by whole body neutron activation analysis. Injections of clomiphene (20 mg/kg/week) kept ovariectomized rats in positive calcium balance at 2.0 +/- 0.5 mg/day. Reductions in total femur calcium content, cortical thickness, and visible trabeculae of femurs in ovariectomized animals were prevented by chronic clomiphene administration. These results in animals suggest a possible new line of investigation of the use of antiestrogenic drugs as therapeutic agents for hormone-dependent osteoporosis in animals and humans.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423228     DOI: 10.1007/bf02405304

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Feasibility study: in vivo neutron activation for regional measurement of calcium using californium 252.

Authors:  H J Evans; A D LeBlanc; P C Johnson
Journal:  Med Phys       Date:  1976 May-Jun       Impact factor: 4.071

2.  Microscopic and ultrastructural changes of hormone-dependent rat mammary cancer treated with "anti-hormones".

Authors:  C Pape; J Ahrens; K D Schulz
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1973

3.  Osteoporosis after oophorectomy in the mature female rat and the effect of oestrogen and-or progestogen replacement therapy in its prevention.

Authors:  J M Aitken; E Armstrong; J B Anderson
Journal:  J Endocrinol       Date:  1972-10       Impact factor: 4.286

4.  The effect of cis- and trans-clomiphene citrate on the collagen content of fetal bone.

Authors:  J A Souma; L D Marshall; R W Abdul-Karim
Journal:  Toxicol Appl Pharmacol       Date:  1972-10       Impact factor: 4.219

5.  Changes in skeletal mass and fragility with castration in the rat; a model of osteoporosis.

Authors:  P D Saville
Journal:  J Am Geriatr Soc       Date:  1969-02       Impact factor: 5.562

6.  Kinetic parameters of calcium metabolism and femur morphometry in rats. I. Influence of sex and age.

Authors:  M Blanusa; M Bogunović; V Matković
Journal:  Pflugers Arch       Date:  1978-08       Impact factor: 3.657

7.  Effect of 1-alpha-hydroxyvitamin D3 on osteoporosis in rats induced by oophorectomy.

Authors:  J U Lindgren; T S Lindholm
Journal:  Calcif Tissue Int       Date:  1979-04-17       Impact factor: 4.333

8.  The effect of ovarian sex steroids on bone mineral status in the oöphorectomized rat and in the human.

Authors:  R Lindsay; J M Aitken; D M Hart; D Purdie
Journal:  Postgrad Med J       Date:  1978       Impact factor: 2.401

  8 in total
  11 in total

Review 1.  The selective oestrogen receptor modulation: evolution and clinical applications.

Authors:  D W Purdie; S A Beardsworth
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Management of menopause when estrogen cannot be used.

Authors:  R L Young; N S Kumar; J W Goldzieher
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

3.  Nondestructive measurement of bone mineral in femurs from ovariectomized rats.

Authors:  D B Kimmel; T J Wronski
Journal:  Calcif Tissue Int       Date:  1990-02       Impact factor: 4.333

4.  Effects of anti-estrogens on bone in castrated and intact female rats.

Authors:  V C Jordan; E Phelps; J U Lindgren
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

Review 5.  Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Authors:  V Craig Jordan; Angela M H Brodie
Journal:  Steroids       Date:  2006-12-13       Impact factor: 2.668

6.  Skeletal alterations in ovariectomized rats.

Authors:  T J Wronski; P L Lowry; C C Walsh; L A Ignaszewski
Journal:  Calcif Tissue Int       Date:  1985-05       Impact factor: 4.333

7.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: a histomorphometric study.

Authors:  G K Wakley; B L Baum; K S Hannon; R T Turner
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

9.  Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.

Authors:  R R Love; R B Mazess; D C Tormey; H S Barden; P A Newcomb; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

Review 10.  The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Authors:  Philipp Y Maximov; Theresa M Lee; V Craig Jordan
Journal:  Curr Clin Pharmacol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.